This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Plaintiffs oppose motion to transfer Effexor appeal to Federal Circuit

( March 19, 2015, 19:37 GMT | Official Statement) -- MLex Summary: Retailer, third party payor, direct purchaser, and end-payor plaintiffs filed oppositions to Wyeth and Teva Pharmaceuticals’ motion to transfer to the US Court of Appeals for the Federal Circuit an appeal of a decision dismissing claims that the drug makers unlawfully delayed the entry of generic competition for the drug Effexor. The oppositions argue that the Federal Circuit lacks jurisdiction over the appeal because neither of plaintiffs’ two claims “’arise under’ federal patent law.” See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login